RS56135B1 - Kompozicije i metode za lečenje plućne hipertenzije - Google Patents

Kompozicije i metode za lečenje plućne hipertenzije

Info

Publication number
RS56135B1
RS56135B1 RS20170640A RSP20170640A RS56135B1 RS 56135 B1 RS56135 B1 RS 56135B1 RS 20170640 A RS20170640 A RS 20170640A RS P20170640 A RSP20170640 A RS P20170640A RS 56135 B1 RS56135 B1 RS 56135B1
Authority
RS
Serbia
Prior art keywords
compositions
methods
pulmonary hypertension
treating pulmonary
treating
Prior art date
Application number
RS20170640A
Other languages
English (en)
Inventor
Luiz Belardinelli
Hunter Campbell Gillies
Faquan Liang
John Shryock
Suya Yang
Original Assignee
Gilead Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56135(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences filed Critical Gilead Sciences
Publication of RS56135B1 publication Critical patent/RS56135B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
RS20170640A 2010-10-15 2011-10-14 Kompozicije i metode za lečenje plućne hipertenzije RS56135B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39352910P 2010-10-15 2010-10-15
US201161490454P 2011-05-26 2011-05-26
US201161497475P 2011-06-15 2011-06-15
EP11833507.4A EP2637664B1 (en) 2010-10-15 2011-10-14 Compositions and methods of treating pulmonary hypertension
PCT/US2011/056404 WO2012051559A2 (en) 2010-10-15 2011-10-14 Compositions and methods of treating pulmonary hypertension

Publications (1)

Publication Number Publication Date
RS56135B1 true RS56135B1 (sr) 2017-10-31

Family

ID=45939010

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170640A RS56135B1 (sr) 2010-10-15 2011-10-14 Kompozicije i metode za lečenje plućne hipertenzije

Country Status (25)

Country Link
US (3) US20120269898A1 (sr)
EP (2) EP3106163A1 (sr)
JP (2) JP5806320B2 (sr)
KR (2) KR20130069855A (sr)
CN (1) CN103458690B (sr)
AR (1) AR083422A1 (sr)
AU (2) AU2011315891B2 (sr)
BR (1) BR112013008983A2 (sr)
CA (1) CA2814518C (sr)
CY (1) CY1119007T1 (sr)
DK (1) DK2637664T3 (sr)
EA (2) EA201691759A1 (sr)
ES (1) ES2627944T3 (sr)
HR (1) HRP20170848T1 (sr)
HU (1) HUE033346T2 (sr)
LT (1) LT2637664T (sr)
MX (1) MX346730B (sr)
NZ (2) NZ707213A (sr)
PL (1) PL2637664T3 (sr)
PT (1) PT2637664T (sr)
RS (1) RS56135B1 (sr)
SI (1) SI2637664T1 (sr)
TW (1) TWI542580B (sr)
WO (1) WO2012051559A2 (sr)
ZA (1) ZA201302746B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2101777T1 (sl) 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
KR20130069855A (ko) 2010-10-15 2013-06-26 길리애드 사이언시즈, 인코포레이티드 폐 고혈압 치료의 조성물 및 방법
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
US20150125546A1 (en) * 2013-11-06 2015-05-07 Gilead Sciences, Inc. Combination therapy for treating pulmonary hypertension
CN105581990A (zh) * 2014-08-27 2016-05-18 人福医药集团股份公司 安立生坦片剂及其制备方法
AU2016233426B2 (en) * 2015-03-13 2021-08-19 Rita Maria CUNHA DE ALMEIDA Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
EP3496739B1 (en) 2016-07-15 2021-04-28 Acceleron Pharma Inc. Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
CN110087653A (zh) * 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
US20200215065A1 (en) * 2017-07-07 2020-07-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and method for treating pulmonary hypertension
US11464778B2 (en) * 2017-12-26 2022-10-11 Liqmeds Worldwide Limited Liquid oral formulations for sildenafil
CN109406688A (zh) * 2018-09-28 2019-03-01 中国食品药品检定研究院 用于检测产品中违禁药品的标准样品
US20230032813A1 (en) * 2019-11-29 2023-02-02 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics Inc LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN112826944B (zh) * 2021-01-29 2023-08-15 台州职业技术学院 一种安立生坦包合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
WO2006007213A1 (en) 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN101072564A (zh) * 2004-08-26 2007-11-14 恩希赛弗制药公司 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
RS20080484A (en) 2006-04-21 2009-07-15 Pfizer Products Inc., PYRIDINE[3,4-b] PYRAZINONES
SI2101777T1 (sl) 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
US20080139483A1 (en) * 2006-12-12 2008-06-12 Gorczynski Richard J Drug combination for hypertensive disorders
MX2010001255A (es) 2007-07-31 2010-12-06 Gilead Colorado Inc Metabolitos y derivados de ambrisentan.
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
KR20130069855A (ko) 2010-10-15 2013-06-26 길리애드 사이언시즈, 인코포레이티드 폐 고혈압 치료의 조성물 및 방법

Also Published As

Publication number Publication date
PL2637664T3 (pl) 2017-09-29
NZ707213A (en) 2016-12-23
CN103458690A (zh) 2013-12-18
EP2637664A4 (en) 2014-09-10
AU2011315891B2 (en) 2015-08-13
LT2637664T (lt) 2017-11-10
EP2637664B1 (en) 2017-03-29
EP3106163A1 (en) 2016-12-21
KR20130069855A (ko) 2013-06-26
US20140275098A1 (en) 2014-09-18
KR20150002876A (ko) 2015-01-07
TWI542580B (zh) 2016-07-21
AU2016204638B2 (en) 2018-06-07
AR083422A1 (es) 2013-02-21
EA026074B1 (ru) 2017-02-28
AU2016204638A1 (en) 2016-08-04
HUE033346T2 (en) 2017-11-28
CN103458690B (zh) 2016-03-16
WO2012051559A3 (en) 2013-10-17
JP5806320B2 (ja) 2015-11-10
CA2814518A1 (en) 2012-04-19
CA2814518C (en) 2016-09-20
JP2015178528A (ja) 2015-10-08
WO2012051559A2 (en) 2012-04-19
ZA201302746B (en) 2014-06-25
PT2637664T (pt) 2017-06-22
TW201219372A (en) 2012-05-16
NZ610012A (en) 2015-05-29
EA201390428A1 (ru) 2014-02-28
US20120269898A1 (en) 2012-10-25
MX346730B (es) 2017-03-30
BR112013008983A2 (pt) 2016-07-05
JP2014506870A (ja) 2014-03-20
SI2637664T1 (sl) 2017-07-31
US20160346280A1 (en) 2016-12-01
MX2013004190A (es) 2013-07-29
AU2011315891A1 (en) 2013-05-23
EP2637664A2 (en) 2013-09-18
CY1119007T1 (el) 2018-01-10
HRP20170848T1 (hr) 2017-08-25
ES2627944T3 (es) 2017-08-01
DK2637664T3 (en) 2017-06-19
US9549926B2 (en) 2017-01-24
EA201691759A1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
ZA201302746B (en) Compositions and methods of treating pulmonary hypertension
IL250824B (en) Certain amino-pyrimidines, their assemblies, and methods of using them
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
HK1203049A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2534205A4 (en) RHEOLOGY MODIFIER COMPOSITIONS AND METHODS OF USE
EP2603199A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP2542060A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
IL222291A0 (en) Compositions and methods of synthesis of pyridinoylpiperidine
EP2593571A4 (en) SWEETENER COMPOSITIONS AND METHODS OF PRODUCING THE SAME
EP2576579A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATIC FIBROSIS
WO2011137427A9 (en) Compositions and methods for treating pulmonary conditions
EP2622029A4 (en) PRINTING COLORING COMPOSITIONS AND METHOD FOR THEIR USE
HK1189501A1 (zh) 抗體組合物及使用方法
HK1258467A1 (zh) 用於預防和治療心臟肥大的方法和組合物
EP2755668A4 (en) COMPOSITIONS OF HYR1 AND TREATMENT PROCEDURES THEREWITH
EP2566485A4 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
GB201018650D0 (en) Methods and compositions
EP2643015A4 (en) COMPOSITIONS AND METHODS
HK1166953A1 (en) Compositions and methods of use
EP2563923A4 (en) COMPOSITIONS AND METHODS FOR REDUCING SCARS AND TREATING FIBROSIS
WO2011130605A9 (en) Compositions and methods for treating pulmonary hypertension